Welcome to our dedicated page for Siga Technologie news (Ticker: SIGA), a resource for investors and traders seeking the latest updates and insights on Siga Technologie stock.
SIGA Technologies, Inc. (SIGA) is a commercial-stage pharmaceutical company whose news flow centers on its role in health security and orthopoxvirus antivirals. The company regularly issues press releases on its financial results, government contracts, regulatory milestones, and corporate developments, giving investors and observers insight into the performance and direction of the business.
A recurring theme in SIGA’s news is the commercial progress of its flagship antiviral medicine, TPOXX (tecovirimat). Company updates describe product revenues from oral and IV TPOXX, including deliveries to the U.S. Strategic National Stockpile and sales to the U.S. Department of Defense and international customers. Releases also discuss procurement orders, outstanding orders, and the mix of domestic and international product sales.
Regulatory and development milestones are another key news category. SIGA has reported authorizations and approvals of TPOXX in multiple jurisdictions, including approval in Japan under the name TEPOXX for orthopoxvirus-related indications. The company also announces modifications to its BARDA 19C contract that add funding for pediatric development and manufacturing activities, reflecting ongoing development work around TPOXX.
Quarterly and annual earnings releases provide detailed financial statements, highlighting product sales, total revenues, operating income or loss, and net income or loss. These updates often include commentary from management on business performance, health security priorities, and the status of government and international contracts.
In addition, SIGA’s news includes governance and capital allocation items, such as the declaration of special cash dividends and appointments to the board of directors. Together, these disclosures offer a view into SIGA’s financial results, strategic relationships with governments and public health agencies, and its continuing focus on TPOXX as a countermeasure against orthopoxvirus-related diseases.
SIGA (Nasdaq: SIGA) will host a webcast and conference call for a business update at 4:30 P.M. ET on Thursday, May 7, 2026. CEO Diem Nguyen and CFO Daniel Luckshire will participate. The live webcast and archived replay will be available in the Investor Relations section of the company website.
Dial-in numbers and a replay Conference ID (1158847) are provided for domestic and international callers; the replay will be available for two weeks.
SIGA (NASDAQ: SIGA) announced a special cash dividend of $0.60 per share, payable April 23, 2026, to shareholders of record at the close of business on April 7, 2026. The dividend equals the special dividend level declared in April 2025.
The company said this distribution reflects its balance sheet strength and focus on maximizing shareholder value while continuing programs to support government preparedness for potential smallpox outbreaks.
SIGA (Nasdaq: SIGA) reported 2025 results and a business update on March 10, 2026. The company generated $88.0M in product revenues in 2025 and reported $24M of pre-tax operating income, secured $27M of additional U.S. government funding, and received a $13M international procurement order for oral TPOXX in January 2026.
SIGA noted deliveries to the U.S. Strategic National Stockpile in 2025 and expects CHMP guidance on tecovirimat indications in March 2026. A conference call and webcast are scheduled for March 10, 2026 at 4:30 PM ET.
SIGA (Nasdaq: SIGA) will host a business update webcast and conference call on March 10, 2026 at 4:30 P.M. ET. Management participants include CEO Diem Nguyen and CFO Daniel Luckshire. The live webcast and an archived replay will be available via the company's Investor Relations website. Dial‑in numbers and a two‑week replay access with Conference ID 1122478 are provided for domestic and international callers.
SIGA (Nasdaq: SIGA) reported results for the three and nine months ended September 30, 2025, and will host a conference call on November 6, 2025 at 4:30 P.M. ET. For the first nine months of 2025 the company generated $85.8M in product sales and $90.8M total revenues, and reported $33M pre-tax operating income.
Year-to-date activity includes $53M oral TPOXX and $26M IV TPOXX deliveries to the U.S. Strategic National Stockpile, a $26M IV TPOXX procurement order from the U.S. Government, $27M of BARDA 19C funding added in 2025, regulatory approval of TEPOXX in Japan, and a $0.60 special cash dividend paid May 15, 2025.
SIGA (Nasdaq: SIGA) will host a business update webcast and conference call on Thursday, November 6, 2025 at 4:30 P.M. ET following release of third-quarter 2025 results.
Management participants include Diem Nguyen, CEO, and Daniel Luckshire, CFO. The live webcast will be available in the Investor Relations section of the company website and by dialing the domestic or international conference numbers. A replay will be available for two weeks with Conference ID 1141989. Attendees are asked to log in 5–10 minutes before the start time.
SIGA Technologies (NASDAQ: SIGA) reported strong financial results for Q2 2025, with significant product revenue growth. The company generated $79.1 million in product sales, primarily from delivering oral TPOXX ($53 million) and IV TPOXX ($26 million) to the Strategic National Stockpile.
The company secured additional development funding of $27 million under the BARDA 19C contract, including $13 million for the TPOXX pediatric program and $14 million for manufacturing support activities. Net income reached $35.5 million ($0.49 per diluted share), compared to $1.8 million ($0.03 per share) in Q2 2024.
SIGA also declared and paid a special cash dividend of $0.60 per share to shareholders of record as of April 29, 2025.
SIGA Technologies (NASDAQ: SIGA), a commercial-stage pharmaceutical company, has scheduled a business update conference call and webcast for August 5, 2025, at 4:30 PM ET. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire discussing the company's second-quarter 2025 results.
Investors can access the call through a domestic dial-in (1-800-717-1738) or international dial-in (1-646-307-1865). A replay will be available for two weeks, and the webcast will be accessible through SIGA's investor relations website.
SIGA Technologies (NASDAQ: SIGA), a commercial-stage pharmaceutical company, has scheduled a business update conference call and webcast for May 8, 2025, at 4:30 P.M. ET. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire discussing the company's first-quarter 2025 results.
Investors can access the call through the company's website at www.siga.com or by dialing 1-800-717-1738 (domestic) or 1-646-307-1865 (international). A two-week replay will be available via phone using Conference ID: 1160299.